register

News & Trends - MedTech & Diagnostics

First blood test for prostate cancer to be a game-changer in clinical management

Health Industry Hub | April 17, 2023 |

MedTech & Diagnostics News: A revolutionary cancer test aims to reduce the stress and anxiety experienced by an estimated 17,000 Australian men being tested for prostate cancer each year in Australia, while also reducing unnecessary burden on the healthcare system.

Minomic led the development of the project to provide urologists with additional information to guide their clinical decisions instead of relying on the results from screening tests such as the Prostate-Specific Antigen (PSA) test which can return poor specificity (false positives) and poor sensitivity (false negatives).

The Micheck Prostate cancer test, which is now available via Douglas Hanley Moir, went through extensive consultation and collaboration with a panel of urologists in Australia, United States and United Kingdom.

“Delivery of MiCheck Prostate to Australians in under 12 months was only possible with the support and guidance of outstanding project partners, including Douglass Hanley Moir and Macquarie University,” said Dr Brad Walsh, CEO of Minomic. 

“The 12-month program would not have been possible without the considerable support of the Advanced Manufacturing Growth Centre with its co-investment allowing us to bring to market a useful test for the risk of aggressive prostate cancer.”

The test is designed for use initially as an adjunct to an abnormal PSA result prior to prostate biopsy. Pathology labs processing blood samples will test the 3 MiCheck blood markers. The result plus the clinical factor is sent to the MiCheck Web Portal where the MiCheck cloud-based algorithm analyses the result and returns a completed report to the pathology lab for onward transmission to the clinician.

“Minomic typifies the ever-advancing Australian manufacturer. They have taken a great idea and turned it into a product that will improve patient outcomes both locally and globally,” said Dr Jens Goennemann, Managing Director of Advanced Manufacturing Growth Centre (AMGC). 

“Minomic’s MiCheck Prostate will provide clinicians with additional technology in prostate cancer decision-making, and it could reduce the cost burden of invasive procedures on the health system, and save lives,” Dr Goennemann added. 

The commercial launch of this revolutionary blood test is expected to create 11 new jobs and boost the company’s revenues by $162 million over the next five years. 

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) […]

More


News & Trends - Pharmaceuticals

Is the imposed PBS funding cap driving the migraine medicines shortage?

Is the imposed PBS funding cap driving the migraine medicines shortage?

Health Industry Hub | February 23, 2024 |

Pharma News: Australia finds itself grappling with an unparalleled shortage of migraine prevention medicines, leaving a significant impact on the […]

More


News & Trends - Pharmaceuticals

MSAC rejects Janssen's CAR T therapy despite clinical superiority, citing need for 'substantial price reduction'

MSAC rejects Janssen’s CAR T therapy despite clinical superiority, citing need for ‘substantial price reduction’

Health Industry Hub | February 23, 2024 |

Pharma News: The Medical Services Advisory Committee (MSAC) has deferred its decision on whether Janssen’s CAR T-cell therapy Carvykti (cilta-cel) […]

More


News & Trends - Pharmaceuticals

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Health Industry Hub | February 23, 2024 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted approval for the first endometriosis treatment in 13 years. Gedeon Richter […]

More


This content is copyright protected. Please subscribe to gain access.